OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Dr. Sborov on Managing Bispecific Antibody–Related Adverse Effects in Multiple Myeloma

September 29, 2021
Douglas W. Sborov, MD, MS
Video

In Partnership With:

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Douglas W. Sborov, MD, MS, assistant professor, Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine; director, Multiple Myeloma Program and Division of Hematology Biorepository; member, Huntsman Cancer Institute (HCI) Experimental Therapeutics Program; physician leader, Multiple Myeloma/Bone Marrow Transplant arm, HCI Clinical Trials Office; and member, HCI Protocol Review and Monitoring Committee, Huntsman Translational Scholar, University of Utah Health, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Low-grade cytokine release syndrome (CRS) is one of the main toxicities associated with bispecific antibodies, Sborov says. Early intervention with tocilizumab (Actemra) was met with hesitation initially because it was unknown whether it would negatively affect the efficacy of bispecific antibodies. However, the field now intervenes with tocilizumab even at the onset of grade 1 CRS, which improves the tolerability of the bispecific agent and does not decrease efficacy, Sborov explains.

However, given the COVID-19 pandemic, many institutions are experiencing a shortage with tocilizumab, which is pushing the field to evaluate other CRS management strategies, such as siltuximab (Sylvant) and anakinra (Kineret), Sborov says.

Related Videos
Matthew Pierre Deek, MD
Bradford (Brad) S. Hoppe, MD, MPH
Michael Chuong, MD, FACRO,
Jiye Liu, MD
Mitchell Machtay, MD, associate dean, Clinical Cancer Research, professor, endowed Chair in Cancer Clinical Research, Department of Radiation Oncology, professor, Department of Medicine, Penn State College of Medicine
Biagio Ricciuti, MD
Damon R. Reed, MD
Ana Velázquez Mañana, MD
Jeremy C. Jones, MD
Related Content

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

September 30th 2023

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30th 2023

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

September 29th 2023

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

September 29th 2023

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

September 30th 2023

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30th 2023

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

September 29th 2023

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

September 29th 2023

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

September 30th 2023

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30th 2023

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

September 29th 2023

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

September 29th 2023
Related Content
Advertisement
Jonathan Kaufman, MD

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

September 30th 2023
Article
Ajay K. Nooka, MD, MPH, FACP

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023
Podcast
Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30th 2023
Article
Saad Z. Usmani, MD, MBA, FACP

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023
Podcast
Darrell White, MD, FRCPC

IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

September 29th 2023
Article
Blood Cancer ©  stock.adobe.com

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

September 29th 2023
Article

Latest Conference Coverage

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact